Attractively, the FeN4O2-SACs treatment has largely weakened the M5-stimulated psoriasis-like morbidity status and shows inhibited cell proliferation and reduced TNF-α, IL-6, and IL-8 mRNA expressions (Fig. 5d, e). The gene discussed is IL6; the disease is psoriasis.